Tech sheet: Dr. Reddy's Enzalutamide API Offerings
Enzalutamide is an androgen receptor inhibitor that acts on different steps in the androgen receptor signalling pathway. Enzalutamide has been shown to inhibit androgen binding to androgen receptors competitively and consequently inhibits nuclear translocation of androgen receptors and their interaction with DNA.
Enzalutamide is presently one of the most promising therapy in the prostate cancer space. It is already an off-patent product in some markets and will be a generic in the United States and Europe by 2028. In 2021, the global market for Enzalutamide is 5.6 metric ton ($4.6 billion).
To know more about our API offerings, please read the technical sheet on Enzalutamide by filling the contact from below.
Explore other Whitepapers:Know More
Complete el formulario de contacto a continuación para ver el documento técnico